International Journal of Clinical Research

Objective To observe the effects of different doses of octreotide in patients with severe acute pancreatitis. Methods Clinical data of 86 patients with severe acute pancreatitis diagnosed and treated in our hospital from July 2022 to July 2023 were retrospectively analyzed. According to the difference of octreotide dosage, they were divided into two groups, of which 0.6mg octreotide per day was classified as the conventional dose group (43 cases), and 1.2mg octreotide per day was classified as the high-dose group (43 cases). The two groups were evaluated from the aspects of treatment effect, symptom resolution time and adverse reactions. Results Compared with the control group, the total clinical effective rate of the observation group increased more significantly, and there was statistically significant significance between the two groups (P < 0.05). Compared with the control group, the regression time of fever, abdominal pain and abdominal distension decreased more significantly in the observation group, with statistically significant significance between the two groups (P < 0.05). Compared with the control group, the total incidence of adverse reactions in the observation group [1] was not statistically significant (P > 0.05). Conclusion The treatment of severe acute pancreatitis with high-dose octreotide is more effective than conventional dose, which can accelerate the resolution of symptoms without increasing adverse reactions.

Severe acute pancreatitis; Different doses; Octreotide